Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
VolitionRx Acquires Nucleosomics Technology Patent from Chroma Therapeutics 12
Partnerships 13
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 13
Singapore Volition to Enter into Agreement with National Taiwan University 14
VolitionRX Extends Research Agreement with University of Bonn 15
Equity Offering 16
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRx Raises USD14.1 Million in Public Offering of Shares 20
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 22
VolitionRx Completes Private Placement Of Shares For US$3 Million 24
Acquisition 25
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 25
VolitionRX Ltd – Key Competitors 26
VolitionRX Ltd – Key Employees 27
VolitionRX Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 29
May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 31
Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 32
Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 34
May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 35
Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 36
Corporate Communications 37
Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 37
Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 38
Government and Public Interest 39
Sep 21, 2017: VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding 39
Other Significant Developments 40
May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 40
Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 41
Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
VolitionRX Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
VolitionRx Acquires Nucleosomics Technology Patent from Chroma Therapeutics 12
VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 13
Singapore Volition to Enter into Agreement with National Taiwan University 14
VolitionRX Extends Research Agreement with University of Bonn 15
VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16
VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17
VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18
VolitionRX Raises USD8.4 Million in Public Offering of Shares 19
VolitionRx Raises USD14.1 Million in Public Offering of Shares 20
VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 22
VolitionRx Completes Private Placement Of Shares For US$3 Million 24
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 25
VolitionRX Ltd, Key Competitors 26
VolitionRX Ltd, Key Employees 27
VolitionRX Ltd, Subsidiaries 28
List of Figures
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
VolitionRX Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
VolitionRX Ltd, Medical Devices Deals, 2012 to YTD 2018 10